TY - JOUR
T1 - NORTRIPTYLINE TREATMENT OF POST-STROKE DEPRESSION
T2 - A DOUBLE-BLIND STUDY
AU - Lipsey, John R.
AU - Pearlson, Godfrey D.
AU - Robinson, Robert G.
AU - Rao, Krishna
AU - Price, Thomas R.
N1 - Funding Information:
This work was supported in part by the following NIH grants: Research Scientist Development Award (RGR) MH 00163, NS 15178, NS 18622, NS 15133, and NS 9-2302.
PY - 1984/2/11
Y1 - 1984/2/11
N2 - The efficacy of nortriptyline in the treatment of post-stroke depression was assessed by a double-blind study in thirty-four patients. Half of the patients had major depression. There was a significantly greater improvement in depression in patients treated with nortriptyline than in a similar group of placebo-treated patients. Depression was measured by the Hamilton depression scale, Zung depression scale, present state examination, and an overall depression scale. Successfully treated patients had serum nortriptyline levels in the therapeutic range. Post-stroke depressions are common, severe, and longstanding, and the demonstrated efficacy of nortriptyline provides an important addition to the treatments available for stroke patients.
AB - The efficacy of nortriptyline in the treatment of post-stroke depression was assessed by a double-blind study in thirty-four patients. Half of the patients had major depression. There was a significantly greater improvement in depression in patients treated with nortriptyline than in a similar group of placebo-treated patients. Depression was measured by the Hamilton depression scale, Zung depression scale, present state examination, and an overall depression scale. Successfully treated patients had serum nortriptyline levels in the therapeutic range. Post-stroke depressions are common, severe, and longstanding, and the demonstrated efficacy of nortriptyline provides an important addition to the treatments available for stroke patients.
UR - http://www.scopus.com/inward/record.url?scp=0021346860&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021346860&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(84)90356-8
DO - 10.1016/S0140-6736(84)90356-8
M3 - Article
C2 - 6141377
AN - SCOPUS:0021346860
SN - 0140-6736
VL - 323
SP - 297
EP - 300
JO - The Lancet
JF - The Lancet
IS - 8372
ER -